neoCARHP:HER2阳性乳腺癌新辅助去卡铂方案非劣效
neoCARHP是一项多中心随机III期非劣效研究,比较紫杉烷联合曲妥珠单抗和帕妥珠单抗加或不加卡铂(TCbHP vs THP)在II-III期HER2阳性乳腺癌中的疗效与安全性。
要点
- THP方案pCR率64.1%,非劣于TCbHP的65.9%(绝对差异-1.8%,95%CI -8.5至5.0)。
- THP组3-4级不良事件20.7%,低于TCbHP组的34.6%。
- THP组严重不良事件1.3%,低于TCbHP组的4.7%。
核心结论
- 在II-III期HER2阳性乳腺癌新辅助治疗中,THP方案(紫杉烷+曲妥珠单抗+帕妥珠单抗)的pCR率非劣于TCbHP方案(加卡铂),且耐受性更好。
研究设计与样本
- 多中心、随机、III期非劣效研究,纳入774例18岁以上、既往未治疗、II-III期HER2阳性侵袭性乳腺癌女性患者,随机1:1接受6周期每3周一次的TCbHP或THP方案。
- 主要终点为改良意向治疗(mITT)人群(至少接受一剂研究治疗)的乳腺和腋窝pCR率(ypT0/is ypN0),安全性在所有接受治疗患者中评估。
主要发现
- mITT人群共766例(THP组382例,TCbHP组384例);THP组pCR 245例(64.1% [95%CI 59.1-69.0]),TCbHP组253例(65.9% [60.9-70.6])。
- THP组3-4级不良事件发生率20.7%,TCbHP组34.6%;严重不良事件分别为1.3%和4.7%。
- THP组最常见3-4级不良事件:中性粒细胞减少6.8%(TCbHP组16.4%)、白细胞减少5.5%(14.8%)、腹泻2.6%(4.2%)。
- 无治疗相关死亡。
关键数值与推荐
- 非劣效界值未在摘要中报告。
- pCR定义:乳腺和腋窝ypT0/is ypN0。
临床怎么用
- 对于II-III期HER2阳性乳腺癌新辅助治疗,可考虑省略卡铂,采用THP方案以降低毒性并维持pCR率。
局限性
- 摘要未报告长期生存结局(如EFS、OS)。
- 非劣效界值及具体统计假设未在摘要中说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The neoCARHP aimed to investigate the efficacy and safety of investigator-selected taxane (docetaxel, paclitaxel, or nab-paclitaxel) plus trastuzumab and pertuzumab, with carboplatin (TCbHP) or without carboplatin (THP), in stage II and III human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHODS: The neoCARHP was a multicenter, randomized, phase III, noninferiority study. Eligible patients were women age 18 years or older with previously untreated, stage II and III, HER2-positive invasive breast cancer. Patients were randomly assigned (1:1) to receive six 3-week cycles of TCbHP or THP. The primary end point was pathologic complete response (pCR) rate in the breast and axilla (ypT0/is ypN0) in the modified intention-to-treat (mITT) population (all randomly assigned patients receiving at least one dose of study treatment). Safety was evaluated in all patients who received any study treatment. RESULTS: Between April 30, 2021, and August 27, 2024, 774 patients were randomly assigned and 766 were included in the mITT population (382 in THP and 384 in TCbHP). pCR was achieved in 245 (64.1% [95% CI, 59.1 to 69.0]) patients in the THP group and 253 (65.9% [60.9-70.6]) in the TCbHP group (absolute difference, -1.8% [95% CI, -8.5 to 5.0]; odds ratio, 0.93 [95% CI, 0.69 to 1.25]; Pnoninferiority = .0089). The THP group had fewer grade 3 and 4 adverse events (20.7% v 34.6%) and serious adverse events (1.3% v 4.7%) than the TCbHP group. The most common grade 3 and 4 adverse events with THP were neutropenia (6.8% v 16.4% with TCbHP), leukopenia (5.5% v 14.8%), and diarrhea (2.6% v 4.2%). No treatment-associated deaths occurred. CONCLUSION: THP provided noninferior pCR rates and improved tolerability compared with TCbHP. Omitting carboplatin may be applicable in HER2-positive breast cancer.
引用
- Gao HF, Ye GL, Lin Y, et al. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. J Clin Oncol. 2026. PMID: 41576297. doi:10.1200/JCO-25-02176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。